Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-23
2007-01-23
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
10735514
ABSTRACT:
A method of treating movement disorders comprises administering to a human or animal subject in need of treatment a therapeutically effective amount of at least one compound according to the following formula:wherein R3and R4are each independently selected from the group consisting of lower alkyl, phenyl and lower alkyl substituted phenyl, and R1and R2are each independently either a hydrogen atom or a radical of the formulawherein R5and R6are each independently selected from the group consisting of H, lower alkyl, phenyl and lower alkyl substituted phenyl, its pharmaceutically acceptable salts, prodrugs, and metabolites thereof.
REFERENCES:
patent: 3679683 (1972-07-01), Gorbaty
patent: 3930006 (1975-12-01), Wiggins et al.
patent: 4260769 (1981-04-01), Stella et al.
patent: 4628056 (1986-12-01), Levitt et al.
patent: 5456851 (1995-10-01), Liu et al.
patent: 5985856 (1999-11-01), Stella et al.
patent: 6093820 (2000-07-01), Gutman et al.
patent: 6281207 (2001-08-01), Richter et al.
patent: WO-01/39779 (2001-06-01), None
patent: WO 01/79185 (2001-10-01), None
patent: WO 03/063872 (2003-08-01), None
Merck Manual of Diagnosis and Therapy, Seventeenth Edition, Beers et al., ed., (1999), Chapter 179, pp. 1462-1473.
Rev. Neurol., 2001, 32 (6): 520-524; I. Balas et al. “Talamotomia esterotaxica de la enfermedad de Parkinson y otros tipos de temblor. Experiencias de la actividad multiunitaria burst en el talamo basada en semimicroelectrodos”. (English Abstract).
Clinician, May 2001, vol. 19, No. 2, pp. 1-15, “Essential Tremor: A Practical Guide to Evaluation, Diagnosis, and Treatment”.
Movement Disorders, vol. 16, No. 3, 2001 pp. 464-468, William C. Koller, et al. “Long Term Safety and Efficacy of Unilateral Deep Brain Stimulation of the Thalamus in Essential Tremor”.
The New England Journal of Medicine, vol. 345, No. 12, Sep. 2001 pp. 887-891, Elan D. Louis, “Essential Tremor”.
Neurology, Jun. 2000, vol. 54, Suppl 4, S8-S13, Leslie J. Findley, “Epidemiology and Genetics of Essential Tremor”.
Neurology, Jun. 2000 vol. 54, Supp.I 4, S30-S38, William C. Koller et al., “Pharmacologic Treatment of Essential Tremor”.
Archives of Neurology, Apr. 1999, vol. 56, No. 4: 475-480, Alexandre Gironell, et al., “A Randomized Placebo-Controlled Comparative Trial of Gabapentin and Propranolol in Essential Tremor”.
The New England Journal of Medicine, vol. 339, No. 16, Oct. 1998, pp. 1130-1143, Anthony E. Lang, et al. “Parkinson's Disease”, Second of Two Parts.
Movement Disorders, vol. 13, Suppl 3., pp. 90-100, 1998, Paul G. Wasielewski, et al. “Pharmacologic Treatment of Tremor”.
Mayo Clinic Proceedings, vol. 66, No. 10, Oct. 1991, pp. 991-997, Manfred D. Muenter, et al. “Treatment of Essential Tremor With Methazolamide”.
Parkinson's Disease and Movement Disorders, Urban & Schwarzenberg, Inc., 1988, 17: 225-234, Stanley Fahn, et al. “Clinical Rating Scale for Tremor”.
Movement Disorders 2, 1987, (22) 438-458, Leslie J. Findley, “The Pharmacology of Essential Tremor”.
Modern Pharmacology, 2nd Ed., 1986, Ch. 4, pp. 41-64, Theodore E. Gram “Metabolism of Drugs”.
Journal of Neurology, Neurosurgery, and Psychiatry, 1985: 48, No. 9, 911-915, Leslie J. Findley et al., “Primidone in Essential Tremor of the Hands and Head: A Double Blind Controlled Clinical Study”.
C.D. Marsden, Origins of Normal and Pathological Tremor in Movement Disorders:Tremor. Eds. L.J. Findley and R. Capildeo, New York, Oxford University Press, 1984, pp. 37-84 “Origins of Normal and Pathological Tremor”.
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed. Ch. 17, 361-396, William R. Hobbs et al., “Hypnotics and Sedatives; Ethanol”.
Sturfelt, G. et al.: Acute Effects of Barbiturates in Parkinson's Disease, “Acta Medica Scandinavica, Almqvist & Wiksell Periodical Co.;” Stockholm, SE, vo. 201, No. 1/2, 1977, pp. 75-76, XP000937405.
Hamann, M. et al.: “Effects of striatal injections of GABAA receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia,” European Journal of Pharmacology, vol. 443, No. 1-3, May 17, 2002, pp. 59-70, XP002284223.
Bashir, K. et al.: “Clozapine for the control of hemiballismus,” Clinical Neuropharmacology, vol. 17, No. 5, 1994, pp. 477-480, XP009032005.
Sasso, E. et al.: “Double-Blind Comparison of Primidone and Phenobarbital in Essential Tremor,” Neurology, vol. 38, No. 5, 1988, pp. 808-810, XP009032012.
Ondo, W. et al.: “Essential tremor. Treatment Options,” CNS Drugs 1996 New Zealand, vol. 6, No. 3, 1996, pp. 178-191, XP009032012.
International Search Report.
Arch Otolaryngol, vol. 110, Jun. 1984, pp. 394-397, “Spastic Dysphonia and Essential (Voice) Tremor Treated With Primidone”, David E. Hartman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry 1985;48:911-915, “Primidone in Essential Tremor of the Hands and Head: A Double Blind Controlled Clinical Study”, Leslie J. Findley, et al.
Neurology, 1985, 35:1874-1787, “Phenobarbitone in Essential Tremor”, Leslie J. Findley, et al.
Journal of Neurology, Neurosurgery, and Psychiatry 1986;49:64-68, “A Comparison of Primidone, Propranolol, and Placebo in Essential Tremor, Using Quantitative Analysis”, W.P. Gorman, et al.
Neurology, 1986; 36:121-124, “Efficacy of Primidone In Essential Tremor”, William C. Koller, et al.
Clinical Neuropharmacology vol. 10, No. 4, 1987, pp. 342-350, Essential Tremor Variants: Effect of Treatment, William C. Koller, et al.
Acta Neurol Scand., 1987:75:332-340, “Primidone and Propranolol in Essential Tremor: A Study Based on Quantitative Tremor Recording and Plasma Anticonvulsant Levels”, P. Dietrichson, et al.
Neurology, 1988, 38:808-810, “Double-Blind Comparison of Primidone and Phenobarbital In Essential Tremor”; Enrico Sasso, et al.
Clinical Neuropharmacology, vol. 13, No. 3, 1990, pp. 210-223, “Basic Mechanism of Action of Drugs Used in the Treatment of Essential Tremor”, Xiao-Ming Guan, et al.
Clinical Neuropharmacology, vol. 13, No. 1, 1990, pp. 67-76, “Primidone in the Long-Term Treatment of Essential Tremor: A Prospective Study with Computerized Quantitative Analysis”, Enrico Sasso, et al.
Movement Disorders, vol. 6, No. 1, 1991, pp. 65-68, “Quantitative Comparison of Barbiturates in Essential Hand and Head Tremor”, Enrico Sasso, et al.
Gollin Michael A.
Jiang Shaojia Anna
Olson Eric S.
Taro Pharmaceuticals U.S.A. Inc.
LandOfFree
Method of treating movement disorders using barbituric acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating movement disorders using barbituric acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating movement disorders using barbituric acid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3819615